JP2007523215A - 癌治療のためのβ−ラパコンおよびＳ期薬組み合わせ - Google Patents

癌治療のためのβ−ラパコンおよびＳ期薬組み合わせ Download PDF

Info

Publication number
JP2007523215A
JP2007523215A JP2007500925A JP2007500925A JP2007523215A JP 2007523215 A JP2007523215 A JP 2007523215A JP 2007500925 A JP2007500925 A JP 2007500925A JP 2007500925 A JP2007500925 A JP 2007500925A JP 2007523215 A JP2007523215 A JP 2007523215A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
cancer
lapachone
phase drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007500925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007523215A5 (enExample
Inventor
リ・チャン・ジェイ
Original Assignee
アークル・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/060,747 external-priority patent/US20050192360A1/en
Priority claimed from US11/068,459 external-priority patent/US20050197406A1/en
Application filed by アークル・インコーポレーテツド filed Critical アークル・インコーポレーテツド
Publication of JP2007523215A publication Critical patent/JP2007523215A/ja
Publication of JP2007523215A5 publication Critical patent/JP2007523215A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007500925A 2004-02-23 2005-02-23 癌治療のためのβ−ラパコンおよびＳ期薬組み合わせ Withdrawn JP2007523215A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54728704P 2004-02-23 2004-02-23
US11/060,747 US20050192360A1 (en) 1999-04-14 2005-02-18 Method of treatment of pancreatic cancer
US11/068,459 US20050197406A1 (en) 1999-04-14 2005-02-18 Method of treatment of lung cancer
PCT/US2005/005620 WO2005082354A1 (en) 2004-02-23 2005-02-23 Beta-lapachone and s-phase drug combinations for cancer treatment

Publications (2)

Publication Number Publication Date
JP2007523215A true JP2007523215A (ja) 2007-08-16
JP2007523215A5 JP2007523215A5 (enExample) 2008-03-27

Family

ID=34916185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007500925A Withdrawn JP2007523215A (ja) 2004-02-23 2005-02-23 癌治療のためのβ−ラパコンおよびＳ期薬組み合わせ

Country Status (4)

Country Link
EP (1) EP1727536A1 (enExample)
JP (1) JP2007523215A (enExample)
CA (1) CA2556759A1 (enExample)
WO (1) WO2005082354A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523187A (ja) * 2004-02-20 2007-08-16 アルキュール， インコーポレイテッド 癌を処置または予防するためのβ−ラパコンの使用
JP2018516275A (ja) * 2015-04-17 2018-06-21 ナディアンバイオ ナフトキノン系化合物を含む、膵炎を治療又は予防する組成物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2033638A2 (en) * 2004-02-20 2009-03-11 Arqule, Inc. Beta-lapachone for the treatment of pancreatic cancer
CN110478363B (zh) * 2019-08-22 2022-09-06 北京大学 cIMP的药物新用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4244141B2 (ja) * 2000-11-07 2009-03-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 血液腫瘍および血液癌を処置する方法
WO2002056823A2 (en) * 2001-01-18 2002-07-25 Arnold Hoffman Redox therapy for tumors
CA2492772A1 (en) * 2002-07-17 2004-01-22 Chiang J. Li Activated checkpoint therapy and methods of use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523187A (ja) * 2004-02-20 2007-08-16 アルキュール， インコーポレイテッド 癌を処置または予防するためのβ−ラパコンの使用
JP2018516275A (ja) * 2015-04-17 2018-06-21 ナディアンバイオ ナフトキノン系化合物を含む、膵炎を治療又は予防する組成物

Also Published As

Publication number Publication date
CA2556759A1 (en) 2005-09-09
WO2005082354A1 (en) 2005-09-09
EP1727536A1 (en) 2006-12-06

Similar Documents

Publication Publication Date Title
JP6719620B2 (ja) 腫瘍選択的併用療法
US20010016329A1 (en) Methods and compositions for overcoming resistance to biologic and chemotherapy
AU2008304380A1 (en) Azacytidine analogues and uses thereof
KR20100137570A (ko) 약제-내성 종양에서 화학요법제 활성을 증강시키는 ｏｎ01910.ｎａ
EP2101790B1 (en) Combination comprising sapacitibine (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent
WO2019073296A1 (en) LIPOSOMAL FORMULATIONS OF BISANTRENE OR DERIVATIVES OR THE LIKE THEREOF
De SPEC–Medicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies, 12-Month Access, eBook: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies
KR20020013474A (ko) 항-ｂ형 간염 활성을 가진 뉴클레오시드
JP2007523215A (ja) 癌治療のためのβ−ラパコンおよびＳ期薬組み合わせ
WO2007132220A1 (en) Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder
WO2013037043A1 (en) Combination therapy using ribavirin as eif4e inhibitor
CN101355969B (zh) 包含cyc-682和细胞毒性药物的抗增殖性组合
JP2007523190A (ja) 肺癌の治療のためのβ−ラパコンの使用
JP2007523192A (ja) 広域スペクトラム抗癌剤としてのβ−ラパコンの使用
JP2007523191A (ja) 血液腫瘍の治療のためのβ−ラパコンの使用
US20050192247A1 (en) Method of treating cancers
JP2007523193A (ja) 膵癌の治療のためのβ−ラパコンの使用
US20050192360A1 (en) Method of treatment of pancreatic cancer
JP2019506434A (ja) ２’，２’−ジフルオロ−５−アザ−２’−デオキシシチジンまたはそれらのプロドラッグを有するｔｐ５３野生型腫瘍の治療方法
JP2007523189A (ja) 結腸癌の治療のためのβ−ラパコンの使用
US20050197405A1 (en) Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
US20050197406A1 (en) Method of treatment of lung cancer
US20050222246A1 (en) Beta-lapachone is a broad spectrum anti-cancer agent
US20050192361A1 (en) Method of treatment of colon cancer
RU2471486C2 (ru) Противоопухолевое средство для непрерывного внутривенного введения, содержащее цитидиновое производное

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080205

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090512